The CEO stated that they had $19.5 million in the bank...which should be enough money to fund their operations until December. At that point, they're planning to release the TLR on the 6-month AD trial for symptomatic conditions. If the data is positive, the company will have a drug to compete against Aricept...which is a ~ $10 Billion market. If we capture just 20% of that market, we'll have about $2 Billion in sales...which would give us an MC of at least $2 Billion.
Our current MC is about $100 million...so our share price would need to multiply about 20x from its current price to reflect the proper value. (And that doesn't include the speculation of a successful TLR for the 18-month data...which, IMO, should be around 40x from today's SP.)
Just remember, this is all speculation on my part. Biotech is very risky...but it can be very rewarding if you find the right company.
Hope that helps.
abe
Market Data 
Markets 
AI
